CN108349924A - 苯磺酰氨基-苯并呋喃衍生物及其用途 - Google Patents

苯磺酰氨基-苯并呋喃衍生物及其用途 Download PDF

Info

Publication number
CN108349924A
CN108349924A CN201680047716.4A CN201680047716A CN108349924A CN 108349924 A CN108349924 A CN 108349924A CN 201680047716 A CN201680047716 A CN 201680047716A CN 108349924 A CN108349924 A CN 108349924A
Authority
CN
China
Prior art keywords
optionally replaced
compound
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680047716.4A
Other languages
English (en)
Chinese (zh)
Inventor
E.H.成
J.谢
P.郑
O.乌尔费利
G.杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commemorate This Long Kaitelin Cancer Center
Original Assignee
Commemorate This Long Kaitelin Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commemorate This Long Kaitelin Cancer Center filed Critical Commemorate This Long Kaitelin Cancer Center
Publication of CN108349924A publication Critical patent/CN108349924A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680047716.4A 2015-08-12 2016-08-12 苯磺酰氨基-苯并呋喃衍生物及其用途 Pending CN108349924A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562204385P 2015-08-12 2015-08-12
US62/204,385 2015-08-12
US201562253030P 2015-11-09 2015-11-09
US62/253,030 2015-11-09
PCT/US2016/046889 WO2017027841A1 (en) 2015-08-12 2016-08-12 Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
CN108349924A true CN108349924A (zh) 2018-07-31

Family

ID=56740558

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680047716.4A Pending CN108349924A (zh) 2015-08-12 2016-08-12 苯磺酰氨基-苯并呋喃衍生物及其用途

Country Status (7)

Country Link
US (2) US10975051B2 (https=)
EP (1) EP3334713B1 (https=)
JP (1) JP2018529649A (https=)
CN (1) CN108349924A (https=)
AU (2) AU2016306694B2 (https=)
CA (1) CA2990477A1 (https=)
WO (2) WO2017027845A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111904958A (zh) * 2019-05-09 2020-11-10 浙江大学 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10975051B2 (en) 2015-08-12 2021-04-13 Memorial Sloan Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
WO2017087810A1 (en) * 2015-11-20 2017-05-26 Memorial Sloan-Kettering Cancer Center Method for screening inhibitors targeting anti-apoptotic survival pathways
JP2019103077A (ja) * 2017-12-07 2019-06-24 Kddi株式会社 管理装置、管理方法、管理プログラム及び通信システム

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024636A2 (en) * 2000-09-20 2002-03-28 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2014047427A2 (en) * 2012-09-21 2014-03-27 Vanderbilt University Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
CA2363621A1 (en) * 1999-02-26 2000-08-31 The Johns Hopkins University A novel inhibitor of programmed cell death
AU2002305769B2 (en) 2001-05-30 2007-07-19 Georgetown University Small molecule antagonists of Bcl2 family proteins
AU2002360335A1 (en) 2001-11-01 2003-05-12 The Regents Of The University Of Michigan Small molecule inhibitors targeted at bcl-2
WO2005007878A2 (en) * 2003-07-22 2005-01-27 Dana-Farber Cancer Institute, Inc. Method of modulating apoptosis and compositions thereof
WO2008017123A1 (en) 2006-08-11 2008-02-14 The Walter And Eliza Hall Institute Of Medical Research Methods for modulating apoptosis in platelets
US9079970B2 (en) 2008-12-09 2015-07-14 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of MCL-1
WO2011029842A1 (en) 2009-09-10 2011-03-17 Novartis Ag Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer
US8501811B2 (en) * 2010-06-17 2013-08-06 Washington University TASPASE1 inhibitors and their uses
FR2962649B1 (fr) 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
EP2619184B1 (en) 2010-09-24 2018-05-23 The Regents of the University of Michigan Deubiquitinase inhibitors and methods for use of the same
CN103917229A (zh) 2011-09-01 2014-07-09 通用医疗公司 调控皮肤色素沉着的方法
WO2013134376A1 (en) 2012-03-06 2013-09-12 Vanderbilt University Positive allosteric modulators for melanocortin receptors
WO2014109696A1 (en) 2013-01-10 2014-07-17 Alf Grandien Method for immortalization of b cells and uses thereof
US10975051B2 (en) * 2015-08-12 2021-04-13 Memorial Sloan Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
WO2017087810A1 (en) * 2015-11-20 2017-05-26 Memorial Sloan-Kettering Cancer Center Method for screening inhibitors targeting anti-apoptotic survival pathways

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024636A2 (en) * 2000-09-20 2002-03-28 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2014047427A2 (en) * 2012-09-21 2014-03-27 Vanderbilt University Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AVDEENKO A. P. ET AL.: "Reactions of arylsulfonylquinone imines with enamines", 《RUSSIAN JOURNAL OF ORGANIC CHEMISTRY》 *
CAS REGISTRY NUMBER: "848334-57-6；848334-54-3；848334-49-6；848335-86-4", 《STN REGISTRY》 *
CAS REGISTRY NUMBER:: "9428411-36-3", 《STN REGISTRY》 *
SRINIVASARAGHAVAN KANNAN ET AL.: "Discovery of Inhibitors of Schistosoma mansoni HDAC8 by Combining Homology Modeling, Virtual Screening, and in Vitro Validation", 《JOURNAL OF CHEMICAL INFORMATION AND MODELING》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111904958A (zh) * 2019-05-09 2020-11-10 浙江大学 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用

Also Published As

Publication number Publication date
JP2018529649A (ja) 2018-10-11
US20180237406A1 (en) 2018-08-23
US10975051B2 (en) 2021-04-13
EP3334713A1 (en) 2018-06-20
AU2016306694A1 (en) 2018-01-18
US20180237407A1 (en) 2018-08-23
WO2017027841A1 (en) 2017-02-16
WO2017027845A1 (en) 2017-02-16
EP3334713B1 (en) 2021-07-21
AU2021203883A1 (en) 2021-07-08
US11098021B2 (en) 2021-08-24
CA2990477A1 (en) 2017-02-16
AU2016306694B2 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
JP7308146B2 (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
JP7258748B2 (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
CN113993519B (zh) 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途
JP7590185B2 (ja) Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
CN105073768A (zh) Ras抑制剂及其用途
CN114727974A (zh) Hdac6抑制剂及其用途
US10711036B2 (en) MALT1 inhibitors and uses thereof
ES3057234T3 (en) Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
US12522587B2 (en) Cancer treatments targeting cancer stem cells
JP7675070B2 (ja) 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体
AU2021203883A1 (en) Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
KR20250099692A (ko) 세레블론 동원 bcl-xl/bcl-2 이중 분해제
US20240376074A1 (en) Nampt inhibitors and uses thereof
CN108884054A (zh) 用于治疗增殖性疾病的化合物
US12478616B2 (en) PI3K inhibitors and uses thereof
US11014876B2 (en) Polyamine sulfonamides and uses thereof
US20250177391A1 (en) Inhibitors of ddr1 and ddr2 for the treatment of arthritis
US20200062776A1 (en) Hedgehog acyltransferase inhibitors and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731

WD01 Invention patent application deemed withdrawn after publication